HDT Bio is dedicated to making a significant impact in the field of RNA vaccines by continually advancing RNA technology and constantly exploring new avenues for innovation.
With LION™’s unique ability to deliver genetic material and other molecules to cells for various disease states, HDT Bio is well-positioned to address additional indications expanding the possibilities for personalized medicine and disease prevention.
Through constant innovation and by demonstrating the versatility and flexibility of the LION™ platform in various disease indications, HDT Bio is capitalizing on the immense market potential and establishing itself as a dynamic company dedicated to transforming healthcare.
HDT Bio’s COVID-19 vaccine, HDT-301, is in Phase 1 clinical trial in the US. Other COVID-19 vaccines developed using HDT Bio’s AMPLIFY platform have been authorized for use in India (GEMCOVAC-19) and are currently being studied in clinical trials in Brazil (VACCINE RNA MCTI CIMATEC HDT) and South Korea (QTP104). Beyond COVID-19, we are developing vaccines to target numerous life-threatening infectious diseases, including shingles, HIV, tuberculosis, Crimean-Congo hemorrhagic fever virus [CCHFV] (HDT-321) and Nipah virus [NiV] (HDT-331).
Because HDT Bio’s technology platform enables localized, T cell-mediated immunological memory responses, LION™ has the potential to treat or prevent cancer. The company is currently developing vaccines targeting antigens associated with pancreatic, colon, prostate, breast, and other cancers.